Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947388 | 0.85 | P2RX3 (0.43) | P2RX3P2RX2ATM | |
| SCHEMBL2384962 | 0.85 | P2RX3 (0.46) | P2RX3P2RX2ATMROCK2ROCK1 | |
| SCHEMBL2383724 | 0.83 | GRM2 (0.44) | GRM5KLKB1 | |
| SCHEMBL2186358 | 0.83 | GRM2 (0.40) | ROCK2ROCK1GRM5KLKB1 | |
| SCHEMBL2171775 | 0.82 | P2RX3 (0.43) | P2RX3P2RX2ROCK2ROCK1 | |
| SCHEMBL16195102 | 0.80 | KDM4E (0.41) | ATMGRM5KLKB1 | |
| SCHEMBL2172368 | 0.79 | P2RX3 (0.63) | P2RX3P2RX2 | |
| SCHEMBL2171681 | 0.74 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL12757695 | 0.70 | P2RX3 (0.44) | P2RX3P2RX2ROCK2ROCK1BACE1 | |
| SCHEMBL1495761 | 0.70 | P2RX3 (0.47) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | P2RX3 207/4885P2RX2 240/4885ATM 1082/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885ATM 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.